知临集团 APM 深 沪
等待开盘 06-30 09:30:00 美东时间
0.7732
-0.001
-0.10%
华盛通- 最 高0.80
- 今 开0.776
- 成交量 2.29万股
- 最 低 0.7699
- 昨 收 0.774
- 总市值 629.68万
- 52周最高 4.47
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.65
- 委 比 66.67%
- 总股本 814.38万
- 历史最高 332.80
- 量 比 0.51
- 振 幅 3.89%
- 历史最低 0.46
- 每 手 1
- 风险率 0.46%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aptorum Group Announces Collaboration between DiamiR Biosciences and AlzLabs Precision Diagnostics for Alzheimer’s Disease Biomarkers
Aptorum Group and DiamiR Biosciences have entered into a definitive agreement for a merger, with shareholders approving the transaction on June 9, 2026. The merger is expected to close before fiscal 2027, subject to customary closing conditions. Upon completion, DiamiR will become a wholly-owned subsidiary of Aptorum Group, and the combined company will be renamed Niki BioSolutions, Inc. The collaboration between DiamiR and AlzLabs aims to develo...
06-22 12:00
Aptorum Group Announces Shareholder Approval of Proposed Merger with DiamiR Biosciences
Aptorum Group shareholders approve merger with DiamiR Biosciences to form a leading life sciences company focused on improving patient outcomes. The all-stock transaction, expected to close before 2027, will make DiamiR a wholly owned subsidiary of Aptorum. Both companies' shareholders have approved the deal, which aims to accelerate commercialization and drive growth in brain health diagnostics.
06-10 12:00
知临集团2026年6月2日股价下跌8.79% 或受股份合并等因素影响
经济观察网 知临集团2026年6月2日股价异动下跌，或受股份合并、基本面疲弱等因素影响 根据截至2026年6月2日（美东时间）的行情数据，知临集团股价出现显著下...
06-03 04:23
知临集团2025年第四季度财报发布日期待定
经济观察网 纳斯达克上市公司知临集团尚未公布2025年第四季度财报的具体发布日期，投资者需关注后续业绩公告。 以上内容基于公开资料整理，不构成投资建议。
04-15 04:38
Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
Aptorum Group Limited received a notification from the Nasdaq Stock Market regarding non-compliance with the minimum bid price requirement of $1 per share. The company has been granted a 180-day grace period until September 1, 2026, to regain compliance. Aptorum intends to evaluate all options, including a reverse stock split, to restore compliance and maintain its Nasdaq listing.
03-06 21:30
Aptorum Group, DiamiR Biosciences, Instant NanoBiosensors Collaborate To Validate Instant's Automated APOE Testing Platform
Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, DiamiR Biosciences Corp. ("DiamiR"), a developer of innovative
02-02 21:06
Aptorum Group Announces a Collaboration Between DiamiR Biosciences and Instant NanoBiosensors (INB) to Validate INB’s Automated APOE Testing Platform for Alzheimer’s Disease
DiamiR Biosciences and Instant NanoBiosensors (INB) have partnered to validate INB’s automated APOE testing platform for clinical use in DiamiR’s certified laboratory. The APOE gene, particularly the ε4 allele, is a key genetic risk factor for Alzheimer’s disease. This collaboration aims to enhance testing capabilities and explore broader applications. DiamiR, set to become a subsidiary of Aptorum Group, and INB envision this partnership as a fou...
02-02 13:00
Aptorum Group Issues Amended SEC Filing on DiamiR Merger
Aptorum Group Ltd. has issued an amendment to its previous report, clarifying details related to its Agreement and Plan of Merger with DiamiR Biosciences Corp. The amendment includes additional inform...
2025-12-06 05:31
DiamiR To Highlight Potential Of Brain-Enriched, Inflammation-Associated microRNAs As Epigenetic Biomarkers Of Neurodegeneration At CTAD Conference
DiamiR Biosciences Corp. ("DiamiR"), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage
2025-11-19 21:05
Andean Precious Metals Sees Q3 Production Rise, Optimizes Operations for Year-End
Andean Precious Metals ( ($TSE:APM) ) just unveiled an announcement. Andean Pre...
2025-10-16 06:40
